Denali (DNLI) Director Nancy Thornberry Sells Shares

What Happened

• Nancy Thornberry, a director of Denali Therapeutics (DNLI), sold a total of 11,439 shares in two open-market transactions on September 2, 2026, for aggregate proceeds of about $261,928. The filing lists sales of 10,824 shares at a reported weighted-average price of $22.85 ($247,328) and 615 shares at $23.74 ($14,600).
• These sales are reported under a pre-arranged Rule 10b5-1 trading plan adopted June 3, 2026.

Key Details

• Transaction dates: September 2, 2026 (both sales).
• Reported prices and ranges: table prices shown as $22.85 (first block) and $23.74 (second block); footnotes indicate the shares were sold across price ranges (one block ranged $22.54–$23.52; the other $23.59–$23.85). The filer will provide per-price breakdown on request by the SEC, issuer, or a security holder.
• Aggregate proceeds: approximately $261,928.
• Ownership after transaction: the filing excerpt notes 6,408 unvested RSUs are included in reported holdings; the total post-sale share count was not specified in the provided excerpt.
• Timing/filing: Form 4 was filed September 4, 2026, reporting Sep 2 trades (appears filed within the normal Form 4 deadline).
• Transaction code: S = Sale.

Context

• Trades made pursuant to a Rule 10b5-1 plan are pre-set and generally viewed as routine dispositions rather than ad hoc insider timing. The weighted-average price notes mean the shares were executed at multiple prices within the stated ranges.
• Sales do not necessarily indicate a change in the company’s prospects; they represent insider liquidity.